Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?
ABBV's Q2 spotlight is on Skyrizi and Rinvoq as rising immunology sales aim to offset Humira's decline ahead of July 31 earnings.
Bearish
-55.0